ETF Comparison: XBI vs XLV
ETFã®èª¬æ
XBI - SPDR S&P Biotech ETF
The SPDR S&P Biotech ETF (XBI) provides exposure to the biotechnology sector in the United States, offering a diversified portfolio of mid-cap and small-cap securities. The fund tracks the S&P Biotechnology Select Industry Index, using an equal-weighted methodology to balance assets across all components. This ETF is suitable for investors seeking to fine-tune their exposure to the health care sector or those bullish on biotechnology over the long run.
XLV - Health Care Select Sector SPDR Fund
The Health Care Select Sector SPDR Fund is an equity ETF that tracks the Health Care Select Sector Index, providing exposure to the U.S. health care sector. It offers a cost-effective way to invest in a diversified portfolio of large-cap health care companies, making it an attractive option for investors seeking to tilt their exposure towards lower-risk industries or establish a long-term position in the health care sector.
æ¯èŒããŒãã«
| XBI | XLV | |
|---|---|---|
| ãã¡ã³ãå | SPDR S&P Biotech ETF | Health Care Select Sector SPDR Fund |
| Fund Provider | State Street | State Street |
| Index | S&P Biotechnology Select Industry | Health Care Select Sector |
| Asset Class | Equity | Equity |
| Listing | US-listed | US-listed |
| Expense Ratio | 0.35% | 0.09% |
| Inception Date | 2006-01-31 | 1998-12-16 |
| Number Of Holdings | 140 | 64 |
| Region | United States | United States |
| Investment Style | Growth | Growth |
| Market Cap | Blend | Large-Cap |
| Sector | Healthcare | Healthcare |
| Sector Detail | Biotechnology | Health Care |
| Leveraged | Non-leveraged | Non-leveraged |
ããã¯ãã¹ããªãã·ã§ã³
ãµããªãŒ
äž»èŠææš
ããã©ãŒãã³ã¹ææš
ãªã¹ã¯ææš
詳现ãªã¿ãŒã³
ããã©ãŒãã³ã¹åæ
ããã©ãŒãã³ã¹åæã¯ã环ç©ãªã¿ãŒã³ã幎æ«ïŒEoYïŒãªã¿ãŒã³ãSharpeã¬ã·ãªãSortinoã¬ã·ãªãªã©ã®ãªã¹ã¯èª¿æŽæžã¿ææšãéããŠãæè³æŠç¥ã®ãªã¿ãŒã³ãè©äŸ¡ããããã«éå»ããŒã¿ãè©äŸ¡ããŸããããã«ãããæè³å®¶ã¯ããŸããŸãªåžå Žç°å¢ã§ã®çµ¶å¯Ÿçããã³çžå¯Ÿçãªããã©ãŒãã³ã¹ãè©äŸ¡ã§ããŸãã
环ç©ãªã¿ãŒã³
幎æ«ãªã¿ãŒã³ããŒãã«
幎æ«ãªã¿ãŒã³
ãªã¹ã¯åæ
ãªã¹ã¯åæãšã¯ãè³æ¬ã®æå€±ã«ã€ãªããå¯èœæ§ã®ããæœåšçãªãã¬ãã£ãã€ãã³ãã®è©äŸ¡ãæããŸãããªã¹ã¯åæã宿œããããšã§ãæè³ãè¡ãã¹ããã©ããã®å€æã«åœ¹ç«ãŠãããšãã§ããŸããããã¯ãæè³æŠç¥ã®äžè²«æ§ã«å¯Ÿããå©å®³é¢ä¿è ã®ä¿¡é Œãåæ ãããããŒããŠã³ããã©ãã£ãªãã£ãããŒã¿ãªã©ã®ãªã¹ã¯ææšã䜿çšããŠè¡ãããŸãã
ãããŒããŠã³
ãããŒããŠã³ããŒãã«
Monte Carloã·ãã¥ã¬ãŒã·ã§ã³
Monte Carloã·ãã¥ã¬ãŒã·ã§ã³ã¯ãéå»ã®è³ç£äŸ¡æ ŒããŒã¿ããã®ã©ã³ãã ãµã³ããªã³ã°ãéããŠå¹ åºãæœåšçãªçµæãçæããããšã§ãããŒããã©ãªãªã®ãªã¿ãŒã³ãäºæž¬ããããã«äœ¿çšãããçµ±èšçææ³ã§ããããŸããŸãªåžå Žæ¡ä»¶äžã§ã®ããŒããã©ãªãªã®æœåšçãªãªã¹ã¯ãšãªã¿ãŒã³ãè©äŸ¡ããã®ã«åœ¹ç«ã¡ãŸãããã®ã·ãã¥ã¬ãŒã·ã§ã³ã¯åææè³ãèæ ®ããå®é¡ç©ç«ãå®é¡åŒãåºããå²ååŒãåºããªã©ã®ãã£ãã·ã¥ãããŒã·ããªãªããªãã·ã§ã³ã§ã·ãã¥ã¬ãŒãããŸãã
éèŠïŒMonte Carloã·ãã¥ã¬ãŒã·ã§ã³ã«ãã£ãŠçæãããäºæž¬ã¯çŽç²ã«ä»®èª¬çãªãã®ã§ãããå°æ¥ã®ãªã¿ãŒã³ãä¿èšŒãããã®ã§ã¯ãããŸãããæè³å€æã¯ããŸããŸãªèŠå ãèæ ®ããäžã§è¡ãã¹ãã§ãããéå»ã®ããã©ãŒãã³ã¹ã¯å°æ¥ã®çµæã瀺ããã®ã§ã¯ãããŸããã